REGN1500

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

HypertriglyceridemiaMetabolic Disorders

Phase 1

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

CompletedNCT01749878

Regeneron PharmaceuticalsHypertriglyceridemia

Start: 2012-12-31End: 2016-01-31Updated: 2016-05-12

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

CompletedNCT02107872

Regeneron PharmaceuticalsMetabolic Disorders

Start: 2014-04-30End: 2015-09-30Updated: 2015-09-30

Related Papers

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

Circulation2019-06-27235 citations

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

New England Journal of Medicine2017-05-24836 citations